Opioid antagonist treatment in alcohol use disorder: extinction, reward memory, and the possible importance of timing.

Opioid receptor antagonists, particularly naltrexone and nalmefene, are among the best-supported pharmacotherapies for alcohol use disorder (AUD), yet their clinical efficacy remains modest and highly heterogeneous. The mechanisms through which transient opioid receptor blockade produces sustained therapeutic benefit remain incompletely understood. Classical explanations emphasize attenuation of alcohol reward and suppression of craving, whereas extinction-based models propose that therapeutic effects emerge when alcohol consumption occurs under opioid receptor blockade, leading to weakening of conditioned drinking behavior. Clinical findings from targeted or "as-needed" treatment paradigms are broadly consistent with this interpretation. However, available observations are not fully explained by extinction alone. Preclinical animal studies suggest that subsequent alcohol drinking may depend critically on the timing of antagonist administration relative to alcohol exposure, including effects observed when opioid antagonists are administered immediately after drinking. Such findings raise the possibility that post-reward memory processes, including interference with reward-memory consolidation or reconsolidation, may contribute to therapeutic effects. Alternative explanations, including conditioned taste aversion, must also be considered, although the broader human literature more strongly supports modulation of reward and craving than generalized aversion. This mini-review integrates preclinical, clinical, and contemporary memory-neuroscience perspectives on opioid antagonist treatment in AUD. Improved understanding of these timing-dependent mechanisms, and their potential translational relevance to humans, may help explain clinical heterogeneity and guide the development of more targeted pharmacotherapeutic strategies.